Wyatt Shields receives Grubstake Award to advance treatment toward clinical use

Assistant Professor Wyatt Shields

High-grade serous carcinoma is the deadliest form of ovarian cancer, and while a drug called olaparib can help prevent the cancer from returning, it often causes serious side effects. To address this challenge, Wyatt Shields, assistant professor in CU Boulder’s Department of Chemical and Biological Engineering,  Benjamin Bitler, associate professor in the CU Anschutz Division of Reproductive Sciences and CU PhD Student Courtney Bailey have developed a new way to deliver the drug more safely. Their approach uses tiny, biodegradable particles carried by immune cells to deliver treatment directly to tumors, helping reduce harmful effects on the rest of the body. Funding totaling $300,000 from the Gates Institute at University of Colorado Anschutz, in partnership with CU Anschutz Innovations, will support the next steps to move this technology closer to clinical use.

Read more at University of Colorado Anschutz News...